# Message from the Management

We deeply appreciate the exceptional understanding and support that our shareholders have extended to the corporate activities of the NOF Group.

The Group aims to enhance its corporate value into the future as a global company and promotes its business activities in line with the "NOF VISION 2030," its strategic policy. In the first six months of the current fiscal year, which falls in the final stages of the 2025 Mid-Term Management Plan, a stage positioned for expanding profit, although demand declined in the Functional Chemicals Segment except for certain areas, raw materials for DDS drug formulations in the Pharmaceuticals, Medicals and Health Segment performed steadily, making steady progress against the annual plan.

The interim dividend has been set at \(\frac{4}{26}\) per share, and the amount allocated for the purchase of treasury stock has been set at \(\frac{4}{5}\),000 million. In addition, concerning the forecast of our consolidated financial results for the current fiscal year, net sales, operating income, ordinary income, and profit attributable to owners of parent are expected to exceed the results of the previous fiscal year.

The Group provides innovative products and services that meet new needs by responding swiftly to market changes. We will further strengthen our technological development foundation, enhance the specialization of our products and services, and improve quality management, thereby advancing as a corporate group with the spirit of a technology-driven venture company.

Today, the world is facing numerous challenges, including environmental issues such as climate change as well as human rights issues. Working toward the realization of a sustainable society is an obligation that all companies must address. The Group will continue to endeavor to create new value with the power of chemistry, and meet the expectations of all of our stakeholders, thereby continuing to deliver true value to society.

We kindly ask all shareholders for your continuing support.

#### **Business Overview**

During the first six months of the fiscal year under review, the outlook for the global economy deteriorated due to increased risk of a downturn and policy uncertainties in the economy caused by the United States trade policy. The future outlook remained uncertain due to concerns about the impact of the prolonged crisis in Ukraine, the increasingly strained situation in the Middle East, elevated prices of raw materials and fuel, and fluctuations in the financial and capital markets. In Japan, the economy continued to show signs of a moderate recovery as consumer spending has been picking up, despite the impact of the United States trade policy observed mainly in the automotive industry.

In the business environment surrounding the Group, although domestic economic conditions were gradually recovering, the risk of a downturn caused by elevated prices of raw materials and fuel and the impact of tariff measures in the United States was a cause for concern.

Amid this business environment, under the three-year 2025 Mid-Term Management Plan, which ends in the fiscal year ending March 31, 2026, the Group upheld the basic policy of "Practice and Breakthrough." With the basic policy, the Group has tackled its challenges, namely, "Expanding business by addressing changes in markets," "Accelerating new product and new technology development," "Improving productivity," "Pursuing safety and security," and "Promoting CSR," strived to explore new markets, expand sales and reduce production costs, and made continuous management efforts to achieve sustainable growth.

With regard to the initiative of "Expanding business by addressing changes in markets," we have been promoting a shift to a solution business model by enhancing business domain expansion with a focus on the three business fields of life/healthcare, environment/energy, and electronics/IT. In addition, in the current fiscal year, we will aid in the realization of a sustainable society and an ideal chemical industry of the future, conducting the "NOF CORPORATION Open Innovation Program 2025," which calls for the development of next-generation materials and technologies in the electronics field, which is expected to grow, and will promote "Accelerating new product and new technology development."

As a result, for the first six months of the fiscal year ending March 31, 2026, consolidated net sales were \\$109,139 million, a year-on-year decrease of 1.2%. Consolidated operating income was \\$20,648 million, a year-on-year decrease of 11.5%, consolidated ordinary income was \\$21,632 million, a year-on-year decrease of 8.3%, and profit attributable to owners of parent was \\$15,419 million, a year-on-year decrease of 9.4%.

Financial results by segment are as follows.

### (1) Functional Chemicals

In the field of fatty acid derivatives, net sales decreased due to sluggish shipments of environmental/energy products in Asia.

With regard to surfactants, net sales decreased due to sluggish shipments of toiletry products.

In ethylene oxide and propylene oxide derivatives, net sales decreased due to sluggish demand of synthetic resins and resin processing.

In organic peroxides, net sales decreased due to sluggish demand in Japan and Asia.

In special anti-corrosion agents, net sales increased due to steady demand in Japan and overseas.

As a result, in the Functional Chemicals Segment, consolidated net sales were \(\frac{4}{9}\),094 million (down 8.4% year on year), and consolidated operating income was \(\frac{4}{12}\),349 million (down 23.0% year on year).

### (2) Pharmaceuticals, Medicals and Health

Regarding processed edible oils and functional food materials, although the demand for use in bread, confectionary, and processed foods has stabilized, net sales increased due to efforts to maintain fair prices.

In healthcare foods products, net sales increased due to an increase in shipments for health foods.

In biocompatible materials, net sales decreased due to a decrease in shipments for 2-Methacryloyloxyethyl phosphorylcholine (MPC)-related products.

In the field of raw materials for DDS (drug delivery system) drug formations, net sales remained at the same level as the previous period due to steady demand and shipments.

As a result, in the Pharmaceuticals, Medicals and Health Segment, consolidated net sales were \(\frac{\pmathbf{

### (3) Explosive & Propulsion

In industrial explosives, net sales increased.

In the field of space rocket products, net sales increased due to higher shipments of our products for rockets.

In the field of defense-related explosives, net sales increased.

In the field of functional materials and devices, net sales remained at the same level as the previous period. As a result, in the Explosive & Propulsion Segment, consolidated net sales were \(\frac{\pmaterial}{4}\),722 million (up 26.1% year on year), and consolidated operating income was \(\frac{\pmaterial}{4}\),292 million (up 77.8% year on year).

### (4) Others

The Others Segment consists of the transportation and real estate businesses. In the Others Segment, consolidated net sales were \(\frac{\pmathbf{322}}{322}\) million (up 6.4% year on year), and consolidated operating income was \(\frac{\pmathbf{2235}}{2220}\) million (up 29.0% year on year).

# **Consolidated Financial Statements**

Consolidated Balance Sheet

Liabilities for retirement benefits Other long-term liabilities Total liabilities (Net assets) Shareholders' equity Common stock Capital surplus Retained earnings Treasury stock, at cost Accumulated other comprehensive income Unrealized holding gain on securities Translation adjustments Retirement benefits liability adjustments Non-controlling interests Total net assets Total liabilities and net assets	21,617 2,494 3,624 15,498 94,439  246,535 17,742 15,058 230,007 (16,272) 35,613 26,299 5,186 4,127 1,000 283,149 377,588	20,533 19,321 2,008 4,976 12,336 77,646  246,724 17,742 15,058 220,195 (6,271) 31,803 21,072 6,437 4,294 1,022 279,550 357,196
Other long-term liabilities  Total liabilities (Net assets)  Shareholders' equity Common stock Capital surplus Retained earnings Treasury stock, at cost  Accumulated other comprehensive income Unrealized holding gain on securities Translation adjustments Retirement benefits liability adjustments  Non-controlling interests	2,494 3,624 15,498 94,439  246,535 17,742 15,058 230,007 (16,272) 35,613 26,299 5,186 4,127 1,000	19,321 2,008 4,976 12,336 77,646  246,724 17,742 15,058 220,195 (6,271) 31,803 21,072 6,437 4,294 1,022
Other long-term liabilities  Total liabilities (Net assets)  Shareholders' equity Common stock Capital surplus Retained earnings Treasury stock, at cost  Accumulated other comprehensive income Unrealized holding gain on securities Translation adjustments Retirement benefits liability adjustments	2,494 3,624 15,498 <b>94,439</b> <b>246,535</b> 17,742 15,058 230,007 (16,272) <b>35,613</b> 26,299 5,186 4,127	19,321 2,008 4,976 12,336 77,646  246,724 17,742 15,058 220,195 (6,271) 31,803 21,072 6,437 4,294
Other long-term liabilities  Total liabilities (Net assets)  Shareholders' equity Common stock Capital surplus Retained earnings Treasury stock, at cost  Accumulated other comprehensive income Unrealized holding gain on securities Translation adjustments	2,494 3,624 15,498 94,439  246,535 17,742 15,058 230,007 (16,272) 35,613 26,299 5,186	19,321 2,008 4,976 12,336 77,646  246,724 17,742 15,058 220,195 (6,271) 31,803 21,072 6,437
Other long-term liabilities  Total liabilities (Net assets)  Shareholders' equity Common stock Capital surplus Retained earnings Treasury stock, at cost  Accumulated other comprehensive income Unrealized holding gain on securities	2,494 3,624 15,498 <b>94,439</b> <b>246,535</b> 17,742 15,058 230,007 (16,272) <b>35,613</b> 26,299	19,321 2,008 4,976 12,336 77,646  246,724 17,742 15,058 220,195 (6,271) 31,803 21,072
Other long-term liabilities  Total liabilities (Net assets)  Shareholders' equity Common stock Capital surplus Retained earnings Treasury stock, at cost  Accumulated other comprehensive income	2,494 3,624 15,498 <b>94,439</b> <b>246,535</b> 17,742 15,058 230,007 (16,272) <b>35,613</b>	19,321 2,008 4,976 12,336 77,646  246,724 17,742 15,058 220,195 (6,271) 31,803
Other long-term liabilities  Total liabilities (Net assets)  Shareholders' equity Common stock Capital surplus Retained earnings Treasury stock, at cost	2,494 3,624 15,498 <b>94,439</b> <b>246,535</b> 17,742 15,058 230,007 (16,272)	19,321 2,008 4,976 12,336 77,646  246,724 17,742 15,058 220,195 (6,271)
Other long-term liabilities  Total liabilities (Net assets)  Shareholders' equity  Common stock  Capital surplus  Retained earnings	2,494 3,624 15,498 <b>94,439</b> <b>246,535</b> 17,742 15,058 230,007	19,321 2,008 4,976 12,336 77,646  246,724 17,742 15,058 220,195
Other long-term liabilities  Total liabilities  (Net assets)  Shareholders' equity  Common stock  Capital surplus	2,494 3,624 15,498 <b>94,439</b> <b>246,535</b> 17,742 15,058	19,321 2,008 4,976 12,336 77,646 246,724 17,742 15,058
Other long-term liabilities  Total liabilities  (Net assets)  Shareholders' equity  Common stock	2,494 3,624 15,498 <b>94,439</b> <b>246,535</b> 17,742	19,321 2,008 4,976 12,336 77,646 246,724 17,742
Other long-term liabilities  Total liabilities  (Net assets)  Shareholders' equity	2,494 3,624 15,498 <b>94,439</b> <b>246,535</b>	19,321 2,008 4,976 12,336 77,646
Other long-term liabilities  Total liabilities  (Net assets)	2,494 3,624 15,498 <b>94,439</b>	19,321 2,008 4,976 12,336 77,646
Other long-term liabilities  Total liabilities	2,494 3,624 15,498	19,321 2,008 4,976 12,336
Other long-term liabilities	2,494 3,624 15,498	19,321 2,008 4,976 12,336
	2,494 3,624	<b>19,321</b> 2,008 4,976
T 1 1 11 1 1 0 1 1 2 2	2,494	<b>19,321</b> 2,008
Long-term debt	The state of the s	19,321
Long-term liabilities		-
Other current liabilities	37,650	20.522
Accrued bonuses for employees	4,031	3,915
Income taxes payable	6,623	7,682
Current portion of long-term debt	289	816
Short-term bank loans	1,494	1,490
Electronically recorded obligations - operating	1,295	1,580
Notes and accounts payable	21,436	22,305
Current liabilities	72,821	58,325
(Liabilities)	<b>72</b> 004	#0.22 <b>=</b>
Total assets	377,588	357,196
Allowance for doubtful accounts	(70)	(151)
Other assets	6,494	6,928
Assets for retirement benefits	9,608	9,557
Investment securities	49,263	41,864
Investments and other assets	65,296	58,198
Intangible assets	1,805	1,950
Others	45,066	36,241
Land	20,421	20,343
Buildings and structures	28,026	28,483
Property, plant and equipment	93,514	85,069
Fixed assets	160,615	145,218
Allowance for doubtful accounts	(202)	(206)
Other current assets	5,185	4,992
Raw materials and supplies	23,616	22,185
Work in process	10,792	6,722
Merchandise and finished goods	32,182	28,419
operating		
Electronically recorded monetary claims -	3,821	3,561
contract assets	47,042	39,230
Notes and accounts receivable - trade, and	49,842	59,238
Cash and time deposits	91,733	87,064
Current assets	216,973	211,978
(Assets)	(millions of yen)	(millions of yen)
Account item	As of September 30, 2025	As of March 31, 2025

#### Consolidated Statement of Income

Account item	April 1, 2025–	April 1, 2024–
Account item	September 30, 2025	September 30, 2024
	(millions of yen)	(millions of yen)
Net sales	109,139	110,478
Cost of sales	68,181	67,968
Gross profit	40,957	42,510
Selling, general and administrative expenses	20,309	19,188
Operating income	20,648	23,321
Non-operating income	1,324	1,222
Interest and dividend income	834	843
Others	490	378
Non-operating expenses	340	951
Interest expenses	68	65
Others	272	885
Ordinary income	21,632	23,592
Extraordinary income	379	784
Extraordinary losses	111	23
Profit before income taxes	21,899	24,353
Income taxes	6,456	7,305
Profit	15,442	17,047
Profit attributable to non-controlling interests	23	31
Profit attributable to owners of parent	15,419	17,016

### Consolidated Statement of Cash Flows

Account item	April 1, 2025–	April 1, 2024–
Account item	September 30, 2025	September 30, 2024
	(millions of yen)	(millions of yen)
Net cash provided by (used in) operating activities	27,608	15,353
Net cash provided by (used in) investing activities	(7,009)	(8,619)
Net cash provided by (used in) financing activities	(15,261)	(6,703)
Effect of exchange rate changes on cash and cash equivalents	(1,062)	2,760
Net increase (decrease) in cash and cash equivalents	4,274	2,790
Cash and cash equivalents at beginning of year	82,706	87,509
Cash and cash equivalents at end of period	86,981	90,300

(Subsidiaries subject to consolidated financial statements)

Nippon Koki Co., Ltd.

NiGK Corporation

NOF METAL COATINGS ASIA PACIFIC CO., LTD

JAPEX Corp.

YUKA SANGYO CO., LTD.

Changshu NOF Chemical Co., Ltd.

PT. NOF MAS CHEMICAL INDUSTRIES

NOF METAL COATINGS NORTH AMERICA INC.

NOF AMERICA CORPORATION

NOF (Shanghai) Co., Ltd.

NOF EUROPE GmbH

NOF METAL COATINGS EUROPE S.A.

Total number of consolidated subsidiaries: 24 (including the 12 companies indicated above)

# Principal Business (as of September 30, 2025)

The Group's business and main products are as indicated below.

Segment	Products
	Fatty acids and fatty acid derivatives
	Surfactants
	Ethylene oxide and propylene oxide derivatives
Functional Chemicals	Organic peroxides
Functional Chemicals	Petrochemical products (polybutene, etc.)
	Functional polymers
	Electronic materials (LCD materials, etc.)
	Special anti-corrosion agents
Processed edible oils and functional food materials	
Dh	Healthcare foods products
Pharmaceuticals,	Biocompatible materials (MPC polymers, MPC monomers, etc.)
Medicals and Health	Raw materials for DDS drug formulations (activated PEG, functional lipid,
	pharmaceutical surfactants)
	Industrial explosives
Explosive &	Space rocket products
Propulsion	Defense-related explosives
_	Functional materials and devices
Othons	Transportation
Others	Real estate

## **Corporate Information** (as of September 30, 2025)

Name NOF CORPORATION

Established June 1, 1937
Incorporated July 1, 1949
Capital ¥17,742 million

Offices

Head Office 20-3, Ebisu 4-chome, Shibuya-ku, Tokyo, Japan

Regional Offices/Branch Offices Osaka Office (Osaka)

Nagoya Office (Aichi) Fukuoka Office (Fukuoka)

Plants Amagasaki Plant (Hyogo)

Kawasaki Works [Chidori Plant, Daishi Plant, DDS Plant] (Kanagawa)

Oita Works [Oita Plant, LS Oita Plant] (Oita)

Aichi Works [Taketoyo Plant, Kinuura Plant, LS Aichi Plant] (Aichi)

Research Laboratories Advanced Technology Research Laboratory (Ibaraki)

Amagasaki Research Laboratory (Hyogo) Chidori Research Laboratory (Kanagawa) Kinuura Research Laboratory (Aichi)

Functional Foods Research Laboratory (Kanagawa) Life Science Research Laboratory (Kanagawa and Aichi)

## Status of Shareholding (as of September 30, 2025)

Total number of shares authorized 970,000,000 Total number of shares issued 229,944,955

(Excluding 6,579,173 shares of treasury stock, and including 114,100 shares (1,141 units of voting rights) of the Company's stock held by Custody Bank of Japan, Ltd. as trust assets of the Board Benefit Trust (BBT). The 1,141 units

of voting rights are not exercisable.

Number of shareholders 15,655

Major shareholders (Top 10)

Name	Number of shares (thousands)	Percentage of ownership
The Master Trust Bank of Japan, Ltd. (Trust Account)	37,891	16.47
Custody Bank of Japan, Ltd. (Trust Account)	13,950	6.06
Meiji Yasuda Life Insurance Company	9,384	4.08
BNYM AS AGT/CLTS 10 PERCENT	5,636	2.45
Nichiyu Shin Ei Kai	4,796	2.08
STATE STREET BANK AND TRUST COMPANY 505001	4,390	1.90
Nichiyu Kyo Ei Kai	4,021	1.74
GOVERNMENT OF NORWAY	3,060	1.33
JP MORGAN CHASE BANK 385781	3,059	1.33
BNYM AS AGT/CLTS NON TREATY JASDEC	2,979	1.29

Notes: 1. The number of shares is rounded down to the nearest thousand shares.

- 2. Percentage of ownership excludes 6,579,173 shares of treasury stock.
- 3. Percentage of ownership is rounded down to the second decimal place.

Distribution of shares by type of shareholder

Category	Number of shareholders	Shareholder ratio	Number of shares	Shareholding ratio
Government and local public bodies	0	0.00	0	0.00
Financial institutions	30	0.19	76,949,306	32.53
Securities companies	54	0.34	3,215,550	1.35
Other domestic firms	342	2.18	27,948,448	11.81
Foreign corporations, etc.	360	2.29	87,567,150	37.02
Individuals and others	14,868	94.97	34,264,501	14.48
Treasury stock	1	0.00	6,579,173	2.78
Total	15,655	100.00	236,524,128	100.00

Note: Shareholder ratio and Shareholding ratio are rounded down to the second decimal place.

## **Officers** (as of September 30, 2025)

### **Directors**

Chairman & Chief Executive Officer\* Takeo Miyaji Koji Sawamura President & Chief Executive Officer\* Director\* Manabu Saito Director\* Kazuyoshi Yamauchi Outside Director Takashi Kamada Outside Director Izumi Hayashi Masanobu Miyo Director Standing Audit & Supervisory Committee Member Outside Director Audit & Supervisory Committee Member Kunimitsu Ito Outside Director Audit & Supervisory Committee Member Yuriko Sagara Outside Director Audit & Supervisory Committee Member Keiichi Miura

- Notes: 1. Directors Takashi Kamada and Izumi Hayashi, and Directors Audit & Supervisory Committee Members Kunimitsu Ito, Yuriko Sagara and Keiichi Miura are Outside Directors as stipulated in the Companies Act.
  - 2. The Company has designated Directors Takashi Kamada and Izumi Hayashi, and Director Audit & Supervisory Committee Members Kunimitsu Ito, Yuriko Sagara and Keiichi Miura as Independent Directors as stipulated in Rule 436-2 of the Securities Listing Regulations of the Tokyo Stock Exchange.
  - 3. Directors with an asterisk (\*) next to their title concurrently serve as Operating Officers.

### **Operating Officers**

Chief Executive Officer

Chief Executive Officer

CEO

Executive Operating Officer

Naoya Umehara

CFO

In charge of Corporate Planning & Strategy Group, Corporate

Communications Group, and Finance Group

Executive Operating Officer

Satoshi Kataoka

General Manager, Functional Materials Div., in charge of

**Purchasing Group** 

Executive Operating Officer Eui-Chul Kang

General Manager, Corporate R&D Div., in charge of Life

Science Products Group

Executive Operating Officer Manabu Saito

CCO

In charge of Functional Foods Group, Human Resources &

General Affairs Group, and Legal Group

Executive Operating Officer Kazuhito Narumi

General Manager, Explosives & Propulsion Div.

Executive Operating Officer Kazuyoshi Yamauchi

CSQO, General Manager, Corporate Technical Div., in charge

of Systems Group

Operating Officer Tsuyoshi Izumisawa

General Manager, Finance Dept.

Operating Officer Hiroyuki Kajikawa

General Manager, Legal Dept.

Operating Officer Hirofumi Kato

General Manager, Functional Foods Div.

Operating Officer Toshiaki Sakaino

General Manager, Corporate Planning & Strategy Dept.

Operating Officer Motoji Takimizu

General Manager, Information Systems Dept.

Operating Officer Kuniaki Tsuruoka

General Manager, Anti-Corrosion Coatings Group

Operating Officer Junko Hamamoto

General Manager, Corporate Communications Dept.

Operating Officer Yoshitaka Honda

General Manager, Kawasaki Works, General Manager, Chidori Plant, and General Manager, Operations Dept., Kawasaki

Works

Operating Officer Akihisa Maeda

General Manager, Human Resources & General Affairs Dept.

Operating Officer Yuji Yamamoto

General Manager, Life Science Div., and General Manager,

Life Science Business Unit

Note: The hierarchy of Directors and Operating Officers in the same position has been abolished. The above list is in Japanese syllabary order.

CEO (Chief Executive Officer) CFO (Chief Financial Officer)

CCO (Chief Compliance Officer) CSQO (Chief Safety and Quality Officer)

### **Memorandum for Shareholders**

Fiscal year	April 1 to March 31
Annual General Meeting of Shareholders	June
Record date	<ol> <li>(1) Exercise of voting rights at Annual General Meeting of Shareholders:         March 31</li> <li>(2) Year-end dividend: March 31</li> <li>(3) Interim dividend: September 30</li> <li>(4) If necessary, another day may be designated as a record date with a public announcement.</li> </ol>
Method of public notice	We provide public announcements by electronic means.  However, when accidents or other unavoidable reasons prevent us from using the method of electronic announcement, we will make announcements in the <i>Nikkei</i> newspaper.  URL for public announcements: https://www.nof.co.jp (in Japanese)
Share unit	100
Stock listing	Tokyo Stock Exchange, Inc.
Shareholder registry administrator (Special account management institution)	Mizuho Trust & Banking Co., Ltd. 1–3–3, Marunouchi, Chiyoda–ku, Tokyo, Japan

# **General Information on Shares**

General Intollina	tion on shares		
	Shareholders who have an account with a securities company	Shareholders who do not have an account with a securities company (or who have a special account)	
Mailing address		Stock Transfer Agency Department, Mizuho Trust & Banking Co., Ltd. 8-4, Izumi 2-chome, Suginami-ku, Tokyo 168-8507, Japan	
Telephone referral		Toll-free (in Japan): 0120-288-324 (9:00 am-5:00 pm except on weekends and holidays)	
Agencies for procedures such as change of address, change of method for receiving dividends, etc.	Your securities company	Mizuho Trust & Banking Co., Ltd.: Head office and branches nationwide (excluding Trust Lounges)	
Payment of dividends payable	Mizuho Trust & Banking Co., Ltd.: Head office and all branches nationwide Mizuho Bank, Ltd.: Head office and all branches nationwide		
System for electronic provision of materials for general meeting of shareholders (request for delivery of a paper copy)	(Dedicated number for th	Your securities company or Mizuho Trust & Banking Co., Ltd. (Dedicated number for the electronic provision system: 0120-524-324 (9:00 am-5:00 pm except on weekends and holidays))	

## Program That Allows Shareholders to Purchase Additional Shares to Attain a Whole Unit

We offer a program that allows shareholders to purchase additional shares to attain a whole unit.

Any shareholder may request us to sell them the exact number of shares that would constitute one whole unit of shares, together with the shares less than one unit owned by the shareholder. For more details, contact the securities company with which you have an account. If you do not have an account with any securities

companies and instead have opened a special amount, contact our special account management institution (Mizuho Trust & Banking Co., Ltd.).

We will continue acceptance of requests for purchase of shares less than one unit.

The latest IR information, including our financial statements and summaries, are available at our website: https://www.nof.co.jp (in Japanese).